Press Releases

GlobeNewswire, Inc.

CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases,...

GlobeNewswire, Inc.

WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today...

GlobeNewswire, Inc.

BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- OneLayer, the cybersecurity and visibility layer for enterprise private cellular networks, today highlighted four real-world threat patterns its OneLayer Bridge platform is built to catch: unauthorized...

GlobeNewswire, Inc.

Company announcement No. 45 / 2026 Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, September 2, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no....

GlobeNewswire, Inc.

RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief...

GlobeNewswire, Inc.

LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the...

GlobeNewswire, Inc.

PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with...

GlobeNewswire, Inc.

CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders,...

EIN Presswire

FAB26 Boston, the world's largest conference on digital fabrication returns to where it all began to celebrate 25 years of global impact, From July 27–31, 2026 BOSTON, MA, UNITED STATES, July 15, 2026 /⁨EINPresswire.com⁩/ -- The Fab Foundation, in...

EIN Presswire

As Model of Autism Education, NECC Shares Expertise and Counsel with State Officials SOUTHBOROUGH, MA, UNITED STATES, June 24, 2026 /⁨EINPresswire.com⁩/ -- The New England Center for Children® (NECC®), a global leader in autism education and...

GlobeNewswire, Inc.

PLYMOUTH, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the grand opening of the highly anticipated model home at its Toll Brothers at The Pinehills -...

GlobeNewswire, Inc.

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven...

GlobeNewswire, Inc.

Boston, MA, July 15, 2026 (GLOBE NEWSWIRE) -- The Initiative for a Competitive City (ICIC) is now accepting applications from Massachusetts manufacturers for the 2026 Manufacturing Accelerator Program (MAP), a national, virtual executive education...

GlobeNewswire, Inc.

MIAMI, July 16, 2026 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a medical technology company developing next-generation aspiration technology for the treatment of acute ischemic stroke, today announced the close of a $48 million Series B financing.

GlobeNewswire, Inc.

BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D.,...

GlobeNewswire, Inc.

Boston, July 14, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is fundamentally reshaping pharmaceutical development, with AI-driven drug discovery attracting over $2 billion in recent investment as breakthrough technologies cut development...

GlobeNewswire, Inc.

EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients,...

EIN Presswire

BOSTON, MA, UNITED STATES, July 14, 2026 /⁨EINPresswire.com⁩/ -- A three-city investor event series this month will bring together accredited investors, entrepreneurs and startup leaders in Boston, Washington and New York and explore emerging...

GlobeNewswire, Inc.

Issued on behalf of Conexeu Sciences Inc. As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational...

GlobeNewswire, Inc.

7C11 antibody builds on APOE Christchurch variant biology associated with resilience to Alzheimer’s disease, including effects on tau, amyloid and the brain vasculature New non-human primate data demonstrate favorable pharmacokinetic and clear...